Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis.
The records of patients with systemic onset juvenile chronic arthritis were reviewed to study the effects of slow-acting antirheumatic drugs on systemic features of the disease and joint manifestations. Frequency and severity of side effects were also evaluated. The following conclusions resulted from this study. Most children could be treated with an alternate-day corticosteroid regimen. Gold and D-penicillamine treatment was not effective or tolerated during the systemic phase. However, after that phase, joint disease was controlled in 42% and 60% of children, respectively. Chlorambucil treatment was helpful in patients with amyloidosis and in those patients in whom all other drugs had failed. The incidence of side effects of chlorambucil are high, however. Antimalarial drug treatment was well tolerated but ineffective during the systemic phase. It was effective on joint disease alone in 44% of a small number of patients. Azathioprine treatment was well tolerated and effective in 50% of patients.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002699:Chlorambucil / Q000627:therapeutic use; D005260:Female; D006046:Gold / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use; D012189:Retrospective Studies
D000305:Adrenal Cortex Hormones; D000962:Antimalarials; D002699:Chlorambucil; D006046:Gold; D010396:Penicillamine